

Arnau AntolÃ- Gil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9372225/publications.pdf>

Version: 2024-02-01

12
papers

4,433
citations

933447

10
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

8556
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs. <i>Science Immunology</i> , 2023, 8, .	11.9	35
2	Evaluation of Humoral and Cellular Immune Responses to the SARS-CoV-2 Vaccine in Patients With Common Variable Immunodeficiency Phenotype and Patient Receiving B-Cell Depletion Therapy. <i>Frontiers in Immunology</i> , 2022, 13, 895209.	4.8	13
3	The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2200413119.	7.1	110
4	Clinical Significance of Indeterminate QuantiFERON-TB Gold Plus Assay Results in Hospitalized COVID-19 Patients with Severe Hyperinflammatory Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 918.	2.4	15
5	Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1332-1341.e5.	2.9	75
6	Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial. <i>Frontiers in Medicine</i> , 2021, 8, 691712.	2.6	11
7	Genetic Screening for TLR7 Variants in Young and Previously Healthy Men With Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 719115.	4.8	76
8	X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	267
9	Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona. <i>Journal of Clinical Immunology</i> , 2021, 41, 1733-1744.	3.8	66
10	Beneficial effect of corticosteroids in preventing mortality in patients receiving tocilizumab to treat severe COVID-19 illness. <i>International Journal of Infectious Diseases</i> , 2020, 101, 290-297.	3.3	33
11	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,749
12	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,983